New pill tested for rare blood cancers
NCT ID NCT07469891
Summary
This is a first-in-human study to test the safety and find the right dose of an experimental oral drug called PRT12396 for people with certain rare blood cancers. It will enroll about 100 adults with high-risk polycythemia vera or myelofibrosis. The main goal is to see how well the drug is tolerated and to identify a safe dose for future testing, while also checking for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest, LLC
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.